Evidence map›Paper›PMID 39487232›Full record

ArticleScientific reports2024

AVE0991 ameliorates dopaminergic neuronal damage in Parkinson's disease through HOTAIRM1/miR-223-3p/α-synuclein axis.

Rui Duan, Liang Shi, Yang Deng, Jiang Wu, Shiyao Wang, Qiang Peng, Zhongyuan Li, Zhaohan Xu, Feng Wang, Xue Xue and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rui Duan *Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Liang Shi *Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Yang Deng *School of Basic Medicine & Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
Jiang WuDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Shiyao WangDepartment of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Qiang PengDepartment of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Zhongyuan LiDepartment of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Zhaohan XuDepartment of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Feng WangDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China. fengwangcn@hotmail.com.
Xue XueDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China. luoboxue1987@163.com.
Qing GaoDepartment of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China. gaoqing19890205@163.com.

Funding

China Postdoctoral Science Foundation (2022M711666)China Postdoctoral Science Foundation (2023M741764)Natural Science Foundation of Jiangsu Province (BK20220196)the International Joint Research and Development Project of Nanjing (202201030)the International Joint Research and Development Project of Nanjing (202308005)the Medical Science and Technology Program of Nanjing (JQX22006)the National Key Research and Development Program of China (2022YFC2406900)the National Natural Science Foundation of China (82301609)
6 · The paper itself

Abstract

Parkinson's disease (PD) is a prevalent type of neurodegenerative disorder. AVE0991, a non-peptide analogue of Ang-(1-7), by which the progression of PD has been discovered to be ameliorated, but the specific mechanism whereby AVE0991 modulates the progression of PD re-mains unclear. The mice overexpressing human α-syn (A53T) were established to simulate PD pathology, and we also constructed an in vitro model of mouse dopaminergic neurons overexpressing hα-syn (A53T). The [

Indexed as

alpha-SynucleinDopaminergic NeuronsMicroRNAsParkinson DiseaseRNA, Long NoncodingAnimalsApoptosisDisease Models, AnimalHumansMaleMicePeptide FragmentsSubstantia Nigraalpha-SynucleinMicroRNAsMIRN223 microRNA, mousePeptide FragmentsRNA, Long NoncodingAVE0991HOTAIRM1miR-223-3pParkinson’s diseaseα-syn

Identifiers

PMID39487232
PMCPMC11530439

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.